Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung DiseaseGlobeNewsWire • 10/17/22
Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of ShareholdersGlobeNewsWire • 10/03/22
Rubric Capital Management Increases Slate of Proposed Mereo BioPharma Director Nominees to FiveBusiness Wire • 10/03/22
Mereo BioPharma Offered to Settle Proxy Contest with Rubric Capital Management by Putting Rubric Principal and Second New Director on the BoardGlobeNewsWire • 09/26/22
Mereo BioPharma Reports Clinical Update and Interim Biomarker Analysis Presented at ESMO 2022 from ACTIVATE Phase 1b/2 Open Label Study of Etigilimab (Anti-TIGIT Antibody MPH-313) plus Nivolumab (Anti-PD-1 Antibody) in Solid TumorsGlobeNewsWire • 09/12/22
Mereo BioPharma Announces the Presentation of Updated Data From a Phase 1b/2 Study of Etigilimab as a Poster at the 2022 American Society of Clinical Oncology Annual MeetingGlobeNewsWire • 05/26/22
Mereo BioPharma to Host Conferene Call Highlighting Top-line Clinical Data from “ASTRAEUS” Phase 2 Study of AlvelestatGlobeNewsWire • 05/06/22
Mereo BioPharma to Host Conference Call Highlighting Top-line Clinical Data from “ASTRAEUS” Phase 2 Study of AlvelestatGlobeNewsWire • 05/06/22
MEREO BIOPHARMA (MREO) Loses 38.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 04/22/22
Mereo BioPharma to Participate in Fireside Chat at the 21st Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/06/22
Mereo BioPharma Reports Full Year 2021 Financial Results and Recent HighlightsGlobeNewsWire • 03/31/22
Mereo BioPharma to Participate in Fireside Chat at the 11th Annual SVB Leerink Global Healthcare ConferenceGlobeNewsWire • 02/10/22